(firstQuint)Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma).

 This is a Phase I open-label dose escalation study of GC33 in combination with Sorafenib in patients with advanced or metastatic HCC.

 This study is designed to evaluate safety, tolerability, pharmacokinetics, and efficacy.

 Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended Phase II dose has been established.

.

 Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)@highlight

This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.

